NCT05981131Active, not recruiting
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
QUILT-205: Long-Term Follow-Up of Subjects in QUILT-2.005 Phase 1b Trial of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 6 (actual)
- First submitted
- 18 Jul 2023
- Start date
- 17 Aug 2023
- Primary completion date
- 30 Aug 2033
- Lead sponsor
- ImmunityBio, Inc.
- Diseases
- Bladder cancer, Childhood cancers
- NCT number
- NCT05981131
What you commit to
- Study type: Observational
- Participants enrolled: 6
- From 17 Aug 2023 to the primary completion date, 30 Aug 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not applicable
Who the study is looking for
- Enrolled and treated with intravesical N-803 plus BCG in the phase 1b portion of QUILT-2.005.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Island Urology Coordinator of this site? Confirm its status | Honolulu | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.